Mckeown, GB
Brian Mckeown, Oxon GB
Patent application number | Description | Published |
---|---|---|
20120058468 | ADAPTORS FOR NUCLEIC ACID CONSTRUCTS IN TRANSMEMBRANE SEQUENCING - The invention relates to adaptors for sequencing nucleic acids. The adaptors may be used to generate single stranded constructs of nucleic acid for sequencing purposes. Such constructs may contain both strands from a double stranded deoxyribonucleic acid (DNA) or ribonucleic acid (RNA) template. The invention also relates to the constructs generated using the adaptors, methods of making the adaptors and constructs, as well as methods of sequencing double stranded nucleic acids. | 03-08-2012 |
20120100530 | ENZYME MUTANT - The invention relates to constructs comprising a nucleic acid binding protein and a surface. At least one native accessible cysteine residue is removed from the binding protein. The binding protein is attached to the surface via one or more accessible cysteine residues. The removal of other accessible cysteine residues from the protein allows control attachment to the surface. The constructs can be used to generate transmembrane pores having a nucleic acid binding protein attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect each of its component nucleotides by stochastic sensing. | 04-26-2012 |
Brian Mckeown, Chipping Norton GB
Patent application number | Description | Published |
---|---|---|
20110229877 | ENZYME-PORE CONSTRUCTS - The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing. | 09-22-2011 |
Brian Mckeown, Middle Barton Oxon GB
Patent application number | Description | Published |
---|---|---|
20140051069 | ENZYME-PORE CONSTRUCTS - The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing. | 02-20-2014 |
20150031020 | ENZYME-PORE CONSTRUCTS - The invention relates to constructs comprising a transmembrane protein pore subunit and a nucleic acid handling enzyme. The pore subunit is covalently attached to the enzyme such that both the subunit and enzyme retain their activity. The constructs can be used to generate transmembrane protein pores having a nucleic acid handling enzyme attached thereto. Such pores are particularly useful for sequencing nucleic acids. The enzyme handles the nucleic acid in such a way that the pore can detect its component nucleotides by stochastic sensing. | 01-29-2015 |
Ian P. Mckeown, Merseyside GB
Patent application number | Description | Published |
---|---|---|
20100021601 | Stabilising Beverages - A process for stabilising a beverage against haze formation comprising treating the beverage with a stabilising agent comprising a particulate silica having a mean pore diameter of at least 6 nm and which has been modified by interaction with a water-soluble polymer having pendant pyrrolidone groups, the polymer being present on the silica in an amount from 5 to 35 percent by weight with respect to anhydrous weight of silica. | 01-28-2010 |
John Paul Mckeown, Edinburgh GB
Patent application number | Description | Published |
---|---|---|
20090091465 | Monitoring Apparatus and Method - The present invention relates to hand held tool monitoring apparatus ( | 04-09-2009 |
20110049247 | ATTACHMENT ARRANGEMENT - The present invention relates to an attachment arrangement that comprises a body, an attachment component and a fastener. One of the body ( | 03-03-2011 |
20110056151 | WINDTURBINE SUPPORT TOWER WITH PENDULUM-DAMPING MEANS - The present invention relates to a tower ( | 03-10-2011 |
Mark Mckeown, Belfast GB
Patent application number | Description | Published |
---|---|---|
20150373135 | WIDE AREA NETWORK OPTIMIZATION - Wide Area Network optimization is described. In an embodiment, a first proxy server computer intercepts a first message from a client computer to a server computer along a routing path. The first proxy server computer modifying the first message to include an indication that the first proxy server computer is along the routing path. The first proxy server computer forwarding the first message to a next hop of the routing path. The first proxy server computer receiving a message from a second proxy server computer indicating that the second proxy server computer is along the routing path. The first proxy server computer, in response to receiving the second message, enabling a set of optimizations for traffic traveling between the client computer and the server computer. | 12-24-2015 |
Neil B. Mckeown, Gilwern GB
Patent application number | Description | Published |
---|---|---|
20100304112 | MICROPOROUS POLYMER MATERIAL - The present invention relates to a microporous material which is a non-network polymer having a chain comprised of repeating units bonded to each other and each including a first generally planar species and a rigid linker, the linker having a point of contortion such that two adjacent first planar species connected by a rigid linker are held in a non-coplanar orientation, the rigid linker further being such that the polymer chain has a rigid contorted structure, and the polymer being such that said repeating units comprised of the first generally planar species and the rigid linker are bonded predominately to two other such repeating units. | 12-02-2010 |
Neil Bruce Mckeown, South Glamorgan GB
Patent application number | Description | Published |
---|---|---|
20130172433 | Polymers, Their Method of Manufacture and Use Thereof - A method for the manufacture of a polymer is provided, the method comprising: Providing a first monomer, the first monomer comprising a bicyclic diamine moiety, a first nucleophilic group provided on a carbon atom of an aromatic moiety, and a second nucleophilic group provided on a carbon atom of an aromatic moiety; Providing a bridging compound comprising at least two sites vulnerable to nucleophilic attack; and Contacting the first monomer with the bridging compound. Polymers made by said method and uses of such polymers are also disclosed. | 07-04-2013 |
Neil Bruce Mckeown, Cardiff GB
Patent application number | Description | Published |
---|---|---|
20130267616 | Polymerisation Method - A method of forming a polymer is provided, the method comprising: Providing a first monomer comprising one or more aromatic moieties, the first monomer comprising at least two amino groups, each of the amino groups being attached to an aromatic moiety; and contacting said first monomer with formaldehyde or a source of methylene. Polymers made by such a method and uses of such polymers are also described. | 10-10-2013 |
Philip Mckeown, Gateshead GB
Patent application number | Description | Published |
---|---|---|
20110212173 | Controlled Release Treatment of Depression - There is described a pharmaceutical composition for controlled release of an active compound wherein the active compound is selected from the group comprising tramadol, resveratrol, acetaminophen, xorphanol, cinfenoac, furcloprofen, bismuth subsalicylate, enofelast, triflusal, ketorfanol, indriline, furofenac, cizolirtine, dacemazine, demelverine, and fenethazine, and derivatives and/or combinations thereof for the treatment or alleviation of depression. More particularly, there is described an abuse resistant pharmaceutical composition for the treatment of inter alia, depression and controlled release pharmaceutical compositions of related thereto. | 09-01-2011 |
20120190735 | Cancer Cell Apoptosis - There is described a therapeutic agent capable of directly or indirectly having an effect on the proteins N-methyl-D-aspartate (NMDA), Cyclooxygenase-2 (COX-2), Tumour Necrosis factor alpha (TNF-a), Nuclear factor-kappa B (NFKB), Cyclin-dependent kinases, e.g. CDK2/A and CDK5/p25, Histone acetyltransferase (HAT) and Farnesyltransferase, simultaneously, sequentially or separately. There is especially described dexanabinol, or a derivative thereof, as the therapeutic agent. | 07-26-2012 |
20130296437 | Treatment of Depression - There is described a method of treatment of a patient suffering from depression, said method comprising the administration of a sub-analgesic amount of tramadol, or a salt thereof. | 11-07-2013 |
20150072020 | Dexanabinol or a Derivative Thereof for Use in the Treatment of Cancer in Dose Ranges of 2-30 mg/kg - There is described a method of treating cancer in a patient wherein the method comprises the administration of dexanabinol, or a derivative thereof, in an amount of from about 2 mg/kg to about 30 mg/kg, based on the weight of the patient. | 03-12-2015 |
20150093438 | Tramadol for Treating Depression - There is described a sub-analgesic amount of tramadol, or a salt thereof, in the treatment, alleviation or prevention of depression in a patient wherein the sub-analgesic amount is from about 60 to 80 mg, of tramadol or a salt thereof. | 04-02-2015 |
Robert Mckeown, Wirral GB
Patent application number | Description | Published |
---|---|---|
20120076839 | ANTIPERSPIRANT COMPOSITIONS - Anhydrous antiperspirant compositions containing an encapsulated fragrance, in which the encapsulate shell comprises an aminoplast resin, and preferably a melamine/formaldehyde resin. The encapsulates have a weight average particle diameter in the range of 25 to 60 μm, a shell having a measured thickness in the range of from 1 to 10 μm and an average in the range of from 5 to 8 μm, a ratio of the shell thickness to the average particle diameter in the range of from 1:5 to 1:10 and a Hysitron hardness in the range of from 2 MPa to 50 MPa, particularly 15 to 25 MPa, enabling them do be advantageously employed in the anhydrous antiperspirant compositions. | 03-29-2012 |
Robert Mckeown, Bebington GB
Patent application number | Description | Published |
---|---|---|
20100104611 | ANTIPERSPIRANT COMPOSITIONS - Anhydrous antiperspirant compositions comprising particulate antiperspirant active; capsules comprising a shear-sensitive shell which encapsulates perfume; and a carrier for the particulate antiperspirant active and capsules; wherein the capsules have a shell of cross-linked gelatin coacervate having a thickness of from 0.25 to 9 μm and providing from 10 to 40% by weight of the capsules, a volume average particle diameter of from 25 to 70 μm, a ratio of shell thickness to the average particle diameter in the range of from 1:5 to 1:120, and a Hysitron hardness in the range of from 1.5 MPa to 50 MPa. | 04-29-2010 |
20100104613 | ANTIPERSPIRANT OR DEODORANT COMPOSITIONS - It is desirable for antiperspirant or deodorant roll-on compositions to be able to deliver fragrance over an extended period of time after application, but previously contemplated encapsulates were based on starch or similar water-soluble or dispersible shell materials, rendering them ineffective in aqueous emulsions. | 04-29-2010 |
Stephanie Mckeown, Shepshed, Leicestershire GB
Patent application number | Description | Published |
---|---|---|
20150307441 | NEW COMPOUNDS AND USES THEREOF - An anthraquinone compound of formula I (such as the compounds of formulae II to X) and processes for making the same are provided. Pharmaceutical compositions for use in the treatment of cancer, optionally in combination with an agent capable of reducing the level of oxygenation of a tumour, are also provided. Additionally, an option for combination with chemotherapeutic and radiotherapeutic modalities to enhance overall tumour cell kill is provided. Methods for the detection of cellular hypoxia, both in vivo and in vitro, are additionally provided. | 10-29-2015 |
Stephen Carl Mckeown, Hitchin GB
Patent application number | Description | Published |
---|---|---|
20130102611 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. | 04-25-2013 |
20140243346 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. Examples of compounds of the invention include the compounds according to Formula Ia, or a pharmaceutically acceptable salt thereof, and the compounds of the examples. | 08-28-2014 |
20140357641 | IP receptor agonist heterocyclic compounds - The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Formula (I): | 12-04-2014 |
20140357642 | IP receptor agonist heterocyclic compounds - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. | 12-04-2014 |
Stephen Carl Mckeown, Essex GB
Patent application number | Description | Published |
---|---|---|
20090105257 | AMINOPHENYLCYCLOPROPYL CARBOXYLIC ACIDS AND DERIVATIVES AS AGONISTS TO GPR40 - The present invention relates generally to novel therapeutic compounds and more particularly to novel compounds, their use as GPR40 agonists, processes for their manufacture, and intermediates useful in their preparation. | 04-23-2009 |
20090239845 | PYRAZOLE COMPOUNDS AS PROSTAGLANDIN RECEPTORS LIGANDS - Compounds of formula (I) or a pharmaceutically acceptable derivative thereof: wherein Z, R | 09-24-2009 |
Stephen Carl Mckeown, Horsham GB
Patent application number | Description | Published |
---|---|---|
20150376183 | IP Receptor Agonist Heterocyclic Compounds - The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed. | 12-31-2015 |